Edition:
India

Rafael Holdings Inc (RFL.N)

RFL.N on New York Stock Exchange

19.60USD
25 Feb 2020
Change (% chg)

$-0.87 (-4.25%)
Prev Close
$20.47
Open
$20.45
Day's High
$21.11
Day's Low
$18.91
Volume
15,758
Avg. Vol
10,505
52-wk High
$30.51
52-wk Low
$11.40

Latest Key Developments (Source: Significant Developments)

Rafael Pharma Says 100 Patients Enrolled In Pivotal Phase 3 Trial Of Cpi-613
Tuesday, 8 Oct 2019 

Oct 8 (Reuters) - Rafael Holdings Inc ::RAFAEL PHARMACEUTICALS REACHES MILESTONE OF 100 PATIENTS ENROLLED IN PIVOTAL PHASE 3 TRIAL (AVENGER 500) OF CPI-613®️ (DEVIMISTAT) FOR PATIENTS WITH METASTATIC PANCREATIC CANCER.RAFAEL PHARMACEUTICALS REACHES MILESTONE OF 100 PATIENTS ENROLLED IN PIVOTAL PHASE 3 TRIAL (AVENGER 500) OF CPI-613®️ (DEVIMISTAT) FOR PATIENTS WITH METASTATIC PANCREATIC CANCER.  Full Article

Rafael Holdings Acquires Majority Stake In Rafael Pharma
Thursday, 24 Jan 2019 

Jan 23 (Reuters) - Rafael Holdings Inc ::RAFAEL HOLDINGS ACQUIRES MAJORITY STAKE IN RAFAEL PHARMA.RAFAEL HOLDINGS INC - COMPANY AND ITS SUBSIDIARIES NOW HOLD 51.0% OF OUTSTANDING STOCK OF RAFAEL PHARMA.RAFAEL HOLDINGS INC - TOTAL INVESTMENT TO DATE FROM RAFAEL HOLDINGS IN RAFAEL PHARMA INCREASED TO $66.7 MILLION.  Full Article

EMA Grants Orphan Drug Designation To Rafael Pharma’s Devimistat For Treating Patients With Relapsed/Refractory AML
Thursday, 10 Jan 2019 

Jan 10 (Reuters) - Rafael Pharmaceuticals Inc::EMA GRANTS ORPHAN DRUG DESIGNATION TO RAFAEL PHARMACEUTICALS’ DEVIMISTAT (CPI-613®) FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML).  Full Article

Rafael Holdings Q1 Loss Per Share $0.04
Tuesday, 11 Dec 2018 

Dec 10 (Reuters) - Rafael Holdings Inc ::RAFAEL HOLDINGS REPORTS FIRST QUARTER FISCAL YEAR 2019 RESULTS.Q1 REVENUE $1.1 MILLION.Q1 LOSS PER SHARE $0.04.  Full Article

No consensus analysis data available.